Transgene SA (TRGNF)
USD 0.7
(0.0%)
USD 0.7
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 29.6 Million EUR | 3.53% |
| 2022 | 28.59 Million EUR | -17.42% |
| 2021 | 34.62 Million EUR | -1.63% |
| 2020 | 35.2 Million EUR | -29.28% |
| 2019 | 49.78 Million EUR | -30.71% |
| 2018 | 71.84 Million EUR | -1.29% |
| 2017 | 72.78 Million EUR | -4.79% |
| 2016 | 76.44 Million EUR | 2.86% |
| 2015 | 74.32 Million EUR | 7.54% |
| 2014 | 69.11 Million EUR | -0.16% |
| 2013 | 69.22 Million EUR | 13.7% |
| 2012 | 60.88 Million EUR | 16.71% |
| 2011 | 52.16 Million EUR | 30.2% |
| 2010 | 40.06 Million EUR | 33.11% |
| 2009 | 30.1 Million EUR | -7.16% |
| 2008 | 32.42 Million EUR | 86.58% |
| 2007 | 17.37 Million EUR | 27.54% |
| 2006 | 13.62 Million EUR | 0.0% |
| 2004 | 11.26 Million EUR | -0.27% |
| 2003 | 11.29 Million EUR | -3.2% |
| 2002 | 11.67 Million EUR | -8.71% |
| 2001 | 12.78 Million EUR | -2.76% |
| 2000 | 13.15 Million EUR | 15.22% |
| 1999 | 11.41 Million EUR | 0.77% |
| 1998 | 11.32 Million EUR | 19.61% |
| 1997 | 9.46 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 51.36 Million EUR | 73.51% |
| 2024 Q2 | 51.36 Million EUR | 0.0% |
| 2023 Q4 | 29.6 Million EUR | 0.0% |
| 2023 Q3 | 29.6 Million EUR | 7.3% |
| 2023 Q1 | 27.59 Million EUR | -3.51% |
| 2023 Q2 | 27.59 Million EUR | 0.0% |
| 2023 FY | 29.6 Million EUR | 3.53% |
| 2022 Q2 | 31.31 Million EUR | 0.0% |
| 2022 Q1 | 31.31 Million EUR | -9.56% |
| 2022 FY | 28.59 Million EUR | -17.42% |
| 2022 Q4 | 28.59 Million EUR | 0.0% |
| 2022 Q3 | 28.59 Million EUR | -8.69% |
| 2021 Q1 | 34.27 Million EUR | -2.63% |
| 2021 Q2 | 34.27 Million EUR | 0.0% |
| 2021 Q4 | 34.62 Million EUR | 0.0% |
| 2021 FY | 34.62 Million EUR | -1.63% |
| 2021 Q3 | 34.62 Million EUR | 1.02% |
| 2020 Q1 | 45.45 Million EUR | -8.69% |
| 2020 FY | 35.2 Million EUR | -29.28% |
| 2020 Q2 | 45.45 Million EUR | 0.0% |
| 2020 Q3 | 34.73 Million EUR | -23.58% |
| 2020 Q4 | 35.2 Million EUR | 1.34% |
| 2019 Q3 | 49.78 Million EUR | -31.03% |
| 2019 FY | 49.78 Million EUR | -30.71% |
| 2019 Q4 | 49.78 Million EUR | 0.0% |
| 2019 Q1 | 72.17 Million EUR | 0.46% |
| 2019 Q2 | 72.17 Million EUR | 0.0% |
| 2018 Q2 | 71.48 Million EUR | 0.0% |
| 2018 Q4 | 71.84 Million EUR | -0.15% |
| 2018 FY | 71.84 Million EUR | -1.29% |
| 2018 Q3 | 71.94 Million EUR | 0.65% |
| 2018 Q1 | 71.48 Million EUR | -1.78% |
| 2017 Q1 | 73.32 Million EUR | -4.08% |
| 2017 Q2 | 73.32 Million EUR | 0.0% |
| 2017 Q4 | 72.78 Million EUR | 0.0% |
| 2017 FY | 72.78 Million EUR | -4.79% |
| 2017 Q3 | 72.78 Million EUR | -0.74% |
| 2016 FY | 76.44 Million EUR | 2.86% |
| 2016 Q3 | 76.44 Million EUR | -4.51% |
| 2016 Q2 | 80.06 Million EUR | 0.0% |
| 2016 Q1 | 80.06 Million EUR | 7.72% |
| 2016 Q4 | 76.44 Million EUR | 0.0% |
| 2015 Q3 | 74.32 Million EUR | -11.63% |
| 2015 FY | 74.32 Million EUR | 7.54% |
| 2015 Q1 | 84.1 Million EUR | 21.68% |
| 2015 Q2 | 84.1 Million EUR | 0.0% |
| 2015 Q4 | 74.32 Million EUR | 0.0% |
| 2014 Q4 | 69.11 Million EUR | 0.0% |
| 2014 FY | 69.11 Million EUR | -0.16% |
| 2014 Q2 | 81.94 Million EUR | 0.0% |
| 2014 Q1 | 81.94 Million EUR | 18.36% |
| 2014 Q3 | 69.11 Million EUR | -15.65% |
| 2013 FY | 69.22 Million EUR | 13.7% |
| 2013 Q2 | 68.1 Million EUR | 0.0% |
| 2013 Q4 | 69.22 Million EUR | 0.0% |
| 2013 Q3 | 69.22 Million EUR | 1.65% |
| 2013 Q1 | 68.1 Million EUR | 11.85% |
| 2012 Q2 | 60.47 Million EUR | 0.0% |
| 2012 Q4 | 60.88 Million EUR | 0.0% |
| 2012 FY | 60.88 Million EUR | 16.71% |
| 2011 FY | 52.16 Million EUR | 30.2% |
| 2011 Q4 | 52.16 Million EUR | 0.0% |
| 2011 Q2 | 44.93 Million EUR | 0.0% |
| 2010 Q2 | 36.5 Million EUR | 0.0% |
| 2010 FY | 40.06 Million EUR | 33.11% |
| 2010 Q4 | 40.06 Million EUR | 0.0% |
| 2009 Q4 | 30.1 Million EUR | 0.0% |
| 2009 FY | 30.1 Million EUR | -7.16% |
| 2009 Q2 | 30.31 Million EUR | 0.0% |
| 2008 FY | 32.42 Million EUR | 86.58% |
| 2008 Q4 | 32.42 Million EUR | 0.0% |
| 2007 FY | 17.37 Million EUR | 27.54% |
| 2006 FY | 13.62 Million EUR | 0.0% |
| 2005 Q2 | 4.37 Million EUR | 0.0% |
| 2004 Q4 | 11.26 Million EUR | 0.0% |
| 2004 Q2 | 4.87 Million EUR | -3.17% |
| 2004 Q1 | 5.03 Million EUR | -55.4% |
| 2004 FY | 11.26 Million EUR | -0.27% |
| 2003 FY | 11.29 Million EUR | -3.2% |
| 2003 Q3 | 4.28 Million EUR | -10.61% |
| 2003 Q4 | 11.29 Million EUR | 163.53% |
| 2003 Q1 | 4.69 Million EUR | -59.82% |
| 2003 Q2 | 4.79 Million EUR | 2.26% |
| 2002 FY | 11.67 Million EUR | -8.71% |
| 2002 Q4 | 11.67 Million EUR | 183.1% |
| 2002 Q1 | 4.29 Million EUR | -66.41% |
| 2002 Q3 | 4.12 Million EUR | -22.26% |
| 2002 Q2 | 5.3 Million EUR | 23.49% |
| 2001 Q3 | 5.28 Million EUR | -21.03% |
| 2001 Q2 | 6.68 Million EUR | 18.48% |
| 2001 FY | 12.78 Million EUR | -2.76% |
| 2001 Q4 | 12.78 Million EUR | 142.1% |
| 2001 Q1 | 5.64 Million EUR | -57.07% |
| 2000 Q4 | 13.15 Million EUR | 147.37% |
| 2000 Q1 | 6.29 Million EUR | -44.88% |
| 2000 Q2 | 6.23 Million EUR | -0.91% |
| 2000 Q3 | 5.31 Million EUR | -14.71% |
| 2000 FY | 13.15 Million EUR | 15.22% |
| 1999 FY | 11.41 Million EUR | 0.77% |
| 1999 Q4 | 11.41 Million EUR | 0.0% |
| 1998 Q4 | 11.32 Million EUR | 0.0% |
| 1998 FY | 11.32 Million EUR | 19.61% |
| 1997 FY | 9.46 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Bioxytran, Inc. | 3.24 Million USD | -811.063% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 44.461% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -6922.592% |
| SQZ Biotechnologies Company | 50.03 Million USD | 40.836% |
| Intellipharmaceutics International Inc. | 12 Million USD | -146.528% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 59.149% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 49.834% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -668.677% |
| Marizyme, Inc. | 26.67 Million USD | -10.981% |
| Genus plc | 485 Million USD | 93.896% |
| Pharming Group N.V. | 244.07 Million USD | 87.87% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -1372.79% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -1076.516% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -679.079% |
| ContraFect Corporation | 32.53 Million USD | 8.994% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -673.451% |
| IMV Inc. | 37.93 Million USD | 21.954% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -151.354% |
| ONE Bio Corp. | 27.49 Million USD | -7.671% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 61.759% |
| Mesoblast Limited | 188.44 Million USD | 84.29% |
| MultiCell Technologies, Inc. | 1617.67 USD | -1830001.319% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 64.303% |
| Genscript Biotech Corporation | 1.32 Billion USD | 97.767% |
| Neon Bloom, Inc. | 1.22 Million USD | -2314.344% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -475.297% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -208.964% |
| Biomind Labs Inc. | 1.49 Million USD | -1875.495% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -227.409% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -60.867% |
| Skye Bioscience, Inc. | 14.07 Million USD | -110.379% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -1964.705% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -406.708% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -20734.653% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -1394.215% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -212.754% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -14620.36% |
| Accustem Sciences Inc. | 1.07 Million USD | -2643.137% |
| EV Biologics, Inc. | 2.11 Million USD | -1299.718% |
| Q BioMed Inc. | 8.13 Million USD | -264.014% |
| GB Sciences, Inc. | 5.41 Million USD | -446.464% |
| Alpha Cognition Inc. | 7.16 Million USD | -313.202% |
| CSL Limited | 18.62 Billion USD | 99.841% |
| Agentix Corp. | 2.51 Million USD | -1079.221% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 75.064% |
| Enzolytics Inc. | 365.26 Million USD | 91.895% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 67.39 Million USD | 56.073% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -3429.733% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -415.244% |
| argenx SE | 444.95 Million USD | 93.346% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 60.485% |
| HST Global, Inc. | 593.59 Thousand USD | -4887.424% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -1627.246% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -2251.109% |
| Halberd Corporation | 728.71 Thousand USD | -3962.608% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -19.635% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -707.74% |
| Zenith Capital Corp. | 27.56 Thousand USD | -107285.106% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -148.717% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -692.785% |
| AVAX Technologies, Inc. | 3.99 Million USD | -641.284% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -4248.343% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -991.774% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -12304.988% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 7.86 Million USD | -276.619% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -44133.441% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 41.101% |
| Kadimastem Ltd | 3.5 Million USD | -744.683% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | -86.14% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -6270.791% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -107817.472% |
| LadRx Corporation | 2.2 Million USD | -1245.359% |
| Cell Source, Inc. | 15.8 Million USD | -87.294% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -66136.352% |
| Regen BioPharma, Inc. | 5.45 Million USD | -442.453% |
| Regen BioPharma, Inc. | 5.45 Million USD | -442.453% |
| Affymax, Inc. | 8.87 Million USD | -233.728% |
| Mobile Lads Corp. | 1.31 Million USD | -2153.907% |
| Itoco Inc. | 1.65 Million USD | -1690.822% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -1343.045% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -389.42% |
| International Stem Cell Corporation | 5.27 Million USD | -461.02% |
| CytoDyn Inc. | 127.89 Million USD | 76.852% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -70727.053% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -1790.03% |
| Qrons Inc. | 1.48 Million USD | -1888.63% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -168.033% |
| SYBLEU INC | 681.41 Thousand USD | -4244.649% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -3560.388% |
| Rebus Holdings, Inc. | 5.24 Million USD | -464.765% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -385.176% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -4630.677% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -541.2% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 27.786% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -32.967% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -1361.696% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -440.434% |
| Neutra Corp. | 973.52 Thousand USD | -2940.998% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -2.033% |
| PureTech Health plc | 125.58 Million USD | 76.426% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -687.97% |
| IXICO plc | 1.9 Million USD | -1457.918% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -44.211% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 71.347% |
| CSL Limited | 18.62 Billion USD | 99.841% |
| Cellectis S.A. | 249.36 Million USD | 88.128% |